Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by C10H12N2on Jan 05, 2022 4:47am

233 Views

Post# 34284147

The winners and losers of 2021

Bellus Health

PHOTO DAVID BOILY, PRESS ARCHIVES

Bellus stock gained 166% in 2021.

Laval biopharmaceutical capped off a good year by presenting positive clinical trial results for its product in mid-December for the treatment of refractory chronic cough. Bellus stock gained 166% in 2021, and analysts believe the rise is far from over. The six experts who officially follow the title all recommend buying and see, on average, the title jump 45% in 2022.

Quebec inc. on the stock market | The winners and losers of 2021 | Press

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone